Shanghai Kaibao Pharmaceutical Co 300039.SZ · CNY

Its shares trade on Shenzhen under the ticker 300039.SZ. It has been listed since 8 January 2010. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.15bn and net income of CN¥278.6m. At that date it held total assets of CN¥4.78bn and shareholders' equity of CN¥4.42bn.

Shanghai Kaibao Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of Chinese medicine. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2010-01-08. is a China-based company principally engaged in the research, development, manufacture and distribution of Chinese patent drugs. The firm's main product is Tanreqing injection, which is used for treatment of upper respiratory tract infections, such as cold and pneumonia. The firm's products include injections, tablets, capsules, granules, vinum and pills, among others. The firm distributes its products in domestic markets.

Figures and description from our data supplier, not checked against the company's own report.

• Ms. Jingwei MuChairman of the BoardCN¥220,000
• Mr. Youlong ChenChief Financial Officer
• Mr. Yingbin ZhouGeneral Manager, Director, since 2020
• Mr. Jianzhong LiuDeputy General Manager, Director, since 2023
• Shaoyong LiuDeputy General Manager, DirectorCN¥300,000
• Dongsheng XueDeputy General Manager, Director, since 2011CN¥260,000
• Chongbang WangDeputy General ManagerCN¥270,000
• Mr. Tao ZhangDeputy General Manager
• Mr. Yingjun ZhuDeputy General ManagerCN¥220,000
• Mr. Liwang RenSecretary of the Board, DirectorCN¥250,000
• Mingwei FengDirectorCN¥200,000
• Mr. Shuzhong JingDirector

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.